证券代码： 600566 证券简称： 济川药业 公告编号： 2025-046 湖北济川药业股份有限公司 关于 2024 年年度权益分派实施后调整回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 回购股份基本情况 三、 回购价格上限的调整 本次回购股份价格上限由不超过人民币 48 元/股（含）调整为不超过人民币 45.92 元/股（含），具体的价格调整公式如下： 调整后的回购股份价格上限=（调整前的回购股份价格上限-每股现金红利） ÷（1+流通股份变动比例） 每股现金红利=（参与分配的股本总数×实际分派的每股现金红利） ÷总股 本=（919,349,675×2.09）÷921,704,160≈2.08 元/股 根据公司 2024 年度利润分配方案，公司本次权益分派仅进行现金红利分配， 不涉及送股和转增股本，因此，公司流通股不会发生变化，流通股份变动比例为 0。 综上，调整后的回购股份价格上限=（48-2.08）÷（1+0）≈45.92 元/股。 湖北济川药业股份有限公司（以下简称"公司"） ...

重山里 北京植德律师事务所 关于 湖北济川药业股份有限公司 差异化分红事项的 法律意见书 植德(证)字[2025]0023-1 号 二〇二五年六月 北京植德律师事务所 Merits & Tree Law Offices 北京市东城区东直门南大街 1 号来福士中心办公楼 12 层 邮编： 100007 12th Floor, Raffles City Beijing Office Tower, No.1 Dongzhimen South Street, Dongcheng District, Beijing 100007 P.R.C 电话(Tel):010-56500900 传真(Fax):010-56500999 www.meritsandtree.com 北京植德律师事务所 关于 湖北济川药业股份有限公司 差异化分红事项的 本法律意见书仅就本次差异化分红所涉及到的法律问题发表法律意见,并不 对有关会计、审计、验资等专业事项和报告发表意见。本法律意见书中对有关审 计报告、验资报告中某些数据和结论的引述,并不意味着本所对这些数据、结论 的真实性和准确性做出任何明示或默示的保证。对于该等数据、报告的内容,本 所并 ...

湖北济川药业股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600566 证券简称：济川药业 公告编号：2025-045 每股分配比例 A 股每股现金红利2.09元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/27 | － | 2025/6/30 | 2025/6/30 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《公司法》《证券法》《上市公司股份回购规则》《上海证券交易所上市公 司自律监管指引第 7 号--回购股份》等相关规定，上市公司回购专用账户中的股 份以及拟回 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [10][11]. Core Insights - The company focuses on the production and sales of pediatric, respiratory, digestive, gynecological, and other pharmaceutical products, with key products including Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules. The company is also advancing its industrial transformation and upgrading, continuously introducing high-quality BD products since 2021 to empower external expansion and lay a foundation for long-term development [3][7]. Revenue and Profitability - The company's revenue grew from 7.208 billion to 9.655 billion from 2018 to 2023, with a CAGR of 6.02%. The net profit attributable to the parent company increased from 1.688 billion to 2.823 billion during the same period, with a CAGR of 10.83%. In 2024, the company expects revenue of 8.017 billion, a year-on-year decline of 16.96%, and a net profit of 2.532 billion, down 10.32% year-on-year [27][28]. Product Matrix - The company’s core products, Pudilan Anti-inflammatory Oral Liquid and Pediatric Chiqiao Qingre Granules, account for over 75% of total revenue, ensuring stable income. Secondary products include Protein Succinyl Iron Oral Solution, Digestive Health Oral Solution, and Huanglong Cough Granules, which are expected to contribute additional revenue in the medium to long term [8][32]. BD Strategy - Since 2022, the company has implemented stock incentive plans and aims to introduce at least four BD products annually, continuously expanding its new drug pipeline. The first batch of products includes long-acting anti-influenza drugs, oral psoriasis medications, and long-acting growth hormones, which are expected to provide sustained growth momentum [9][38]. Key Product Performance - Pudilan Anti-inflammatory Oral Liquid has become a top product in the market despite exiting provincial medical insurance lists, thanks to retail market expansion and unique dosage forms. Pediatric Chiqiao Qingre Granules, a newly developed syrup form, has also been successfully included in medical insurance, contributing to revenue recovery [43][51]. Financial Forecast - The company forecasts revenues of 7.578 billion, 8.074 billion, and 8.707 billion for 2025-2027, with net profits of 2.257 billion, 2.494 billion, and 2.733 billion respectively, corresponding to EPS of 2.45, 2.71, and 2.97 [10].

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] Delisting and Trading Reminders - ST Gongzhi (000584) will enter the delisting arrangement period starting June 20, 2025[1] - ST Jiuyou (600462) will enter the delisting arrangement period starting June 24, 2025[1] - Haiyue (600387) has 12 trading days remaining until the last trading day[1] - Renle (002336) has 11 trading days remaining until the last trading day[1] - Longyu (603003) has 8 trading days remaining until the last trading day[1] - Pengbo (600804) has 8 trading days remaining until the last trading day[1] - Longjin (002750) has 6 trading days remaining until the last trading day[1] Market Volatility - Lianhua Technology (002250) reported severe abnormal fluctuations[1] - ST Kailin (002425) and ST Xuefa (002485) also reported abnormal fluctuations[2]

Group 1 - The core point of the news is the announcement of a family internal equity structure adjustment at Jichuan Pharmaceutical, which triggers a mandatory general offer for the company's shares by Cao Fei, the son of the actual controller, Cao Longxiang [1][2] - On June 11, Cao Longxiang transferred 10.10% of his shares in Jichuan Holdings to Cao Fei for 10.1 million yuan, resulting in Cao Fei holding 60% of Jichuan Holdings and indirectly controlling 5.17 billion shares of Jichuan Pharmaceutical, which is 56.07% of the total share capital [1] - The general offer price is set at 26.93 yuan per share, requiring a maximum total funding of 9.448 billion yuan, with the offer period lasting from June 18, 2025, to July 17, 2025 [2] Group 2 - Jichuan Pharmaceutical's major shareholder structure remains unchanged after the transfer, with Jichuan Holdings holding 4.17 billion shares, accounting for 45.22% of the total share capital, and the combined holdings of the controlling shareholder and concerted parties reaching 61.15% [1] - The company reported a revenue of 1.525 billion yuan in the first quarter of 2025, a year-on-year decrease of 36.51%, and a net profit attributable to shareholders of 440 million yuan, down 47.91% year-on-year [3] - The decline in revenue is attributed to two main factors: a high base in the first quarter of 2024 and the impact of centralized procurement on the main product, Rabeprazole Sodium Enteric-coated Capsules [3]

Core Viewpoint - The announcement details Mr. Cao Fei's tender offer to acquire shares of Hubei Jichuan Pharmaceutical Co., Ltd., with a focus on the acquisition's timeline, purpose, and conditions [2][3][4]. Group 1: Tender Offer Details - The tender offer is valid from June 18, 2025, to July 17, 2025, with specific conditions regarding the withdrawal of acceptance in the last three trading days [2][6][9]. - Mr. Cao Fei intends to acquire 350,841,357 shares, representing 38.06% of the total share capital of the company, at a price of 26.93 yuan per share [5][6]. - The payment method for the tender offer will be in cash [4][5]. Group 2: Purpose of the Tender Offer - The tender offer is a result of a share transfer agreement between Mr. Cao Longxiang and Mr. Cao Fei, where 10.10% of Jiangsu Jichuan Holding Group Co., Ltd. was transferred to Mr. Cao Fei for 10.1 million yuan, indicating a family restructuring of shareholding [2][3]. - The acquisition aims to fulfill the legal obligation for a comprehensive tender offer, and it does not intend to terminate the listing status of Jichuan Pharmaceutical [3]. Group 3: Procedures for Acceptance - Shareholders can submit their acceptance of the tender offer through designated securities companies during the offer period, with specific codes for the tender offer [7][8]. - Accepted shares will be temporarily held by China Securities Depository and Clearing Corporation Limited during the offer period, and shareholders cannot transfer these shares until the withdrawal process is completed [8][10]. Group 4: Additional Information - The company will provide updates on the progress of the tender offer and will issue a results announcement after the offer period ends [6][13]. - Investors seeking detailed information can refer to the tender offer report published on June 16, 2025, on the Shanghai Stock Exchange website [15].

Group 1 - The actual controller of Jichuan Pharmaceutical, Cao Longxiang, is transferring shares to his son, Cao Fei, which triggers a mandatory tender offer for the company [1][2] - Cao Fei will acquire 351 million shares, representing 38.06% of the total issued shares, with a maximum transaction value of 9.448 billion yuan [1][2] - Following the share transfer, Cao Fei's stake in Jichuan Holdings will increase to 60%, allowing him to indirectly control 517 million shares of Jichuan Pharmaceutical, exceeding the 30% threshold for a mandatory tender offer [2] Group 2 - Jichuan Pharmaceutical is facing significant pressure, with revenue and net profit declining for four consecutive quarters due to price cuts from centralized procurement [4] - In 2024, the company expects to achieve revenue of 8.017 billion yuan, a year-on-year decrease of 16.96%, and a net profit of 2.532 billion yuan, down 10.32% [4] - The company's sales expenses are high at 2.954 billion yuan, accounting for 36.85% of total revenue, while R&D expenses are only 445 million yuan, representing 5.55% of total revenue [4]

Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

证券代码： 600566 证券简称： 济川药业 公告编号： 2025-044 湖北济川药业股份有限公司 关于曹飞先生要约收购公司股份的第一次提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 6 月 16 日披露了《湖北济川药业股份有限公司要约收购报告 书》，曹飞先生自 2025 年 6 月 18 日起要约收购公司股份 350,841,357 股。本次 要约收购的具体情况如下： 一、 本次要约收购的基本情况 1 本次公告为曹飞先生要约收购湖北济川药业股份有限公司（以下简称"上 市公司"或"公司"）股份的第一次提示性公告。 预受要约申报代码：706034，申报简称：济川收购 要约收购支付方式：现金 要约收购有效期：2025 年 6 月 18 日至 2025 年 7 月 17 日。按照本次要 约收购申报程序，本次要约收购期限届满前最后三个交易日（2025 年 7 月 15 日、2025 年 7 月 16 日、2025 年 7 月 17 日），预受股东不得撤回 其对要约的接受。 1.被收 ...